Study Summary
This trial will use a SPECT/CT scan of the kidneys using Tc-99m-tilmanocept to look for changes in the kidneys of diabetics that could indicate different stages of kidney disease.
- Diabetic Kidney Disease
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: Approximately 1 hour
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
3 Treatment Groups
Tilmanocept Dose - 0.20 mg
1 of 3
Tilmanocept Dose - 0.050 mg
1 of 3
Tilmanocept Dose - 0.40 mg
1 of 3
Active Control
120 Total Participants · 3 Treatment Groups
Primary Treatment: Tilmanocept Dose - 0.20 mg · No Placebo Group · Phase 1
Trial Logistics
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 1 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
How many individuals are participating in this medical investigation?
"Affirmative. The details provided on clinicaltrials.gov suggest that this medical trial, which was initially listed on August 6th 2021 is still actively recruiting patients for participation. Around 120 individuals must be enrolled from a single site." - Anonymous Online Contributor
Has the FDA verified the efficacy of Tilmanocept Dose - 0.40 mg?
"Tilmanocept Dose - 0.40 mg safety has only been partially evaluated, thus receiving a score of 1 on our scale from one to three." - Anonymous Online Contributor
Are there still spots available for participants in this experiment?
"Clinicaltrials.gov confirms that, as of 16th February 2022, this clinical trial is actively recruiting individuals to participate. The study first appeared on 6th August 2021." - Anonymous Online Contributor